Babraham Research Campus
46 articles with Abzena
New 50,000-square-foot facility will allow them to expand their services from development and Phase I/II to Phase III and manufacturing.
Abzena, a leading global partnership research organization providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates, has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm.
New service reduces the risk, expenditure and time required for the later stages of antibody development
Bespoke approach generates high affinity antibodies and selects lead candidates with the strongest chances of success in the clinic
Sonnet BioTherapeutics Selects Abzena as Clinical Stage Manufacturing Partner for its IL-12-FHAB cytokine-derived Therapeutic Candidate
Additional benefits of the platform include longer serum half-life and targeted delivery, as well as the potential to enhance the efficacy of other therapies, including checkpoint inhibitors.
Abzena announced the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team.
Abzena Offers Integrated Clinical Translation of Biologics With Launch of ADC Cascade and Biologics Cascade
These ex-vivo platform approaches allow efficacy and safety studies against clinically characterized on and off-target tissues.
Abzena Announces Successful Technical Transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) Technology to Enable Use in Client Projects
Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ and HydraSpace™.
Abzena Expands Leadership Team With Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer
Abzena, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer.
Abzena Announces 14-Month Cell Line to Phase 1 GMP Service and Appointment of Shahram Katousian as Head of Biologics Manufacturing
Abzena, the leading biotherapeutics target to GMP partner research organization (PRO) announced an accelerated program to IND. This reduces timeline from stable pool to GMP down to 14 months.
Abzena Expands Management Team: Appoints Campbell Bunce to the Role of Chief Scientific Officer and Bo Adair as Senior Vice President Process and Operations
Abzena, the leading global biologics target to GMP partner research organisation, announced it has appointed Dr Campbell Bunce as Chief Scientific Officer (CSO) and Bo Adair MBA as Senior Vice President Process and Operations.
Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development
Abzena announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service to assist customers in selecting and developing the best lead candidate to take forward for manufacture.
Addition of experienced leadership in GMP Quality as Abzena increases capacity in biologics and complex small molecule manufacturing
Abzena Announces Expansion of Integrated Biologics Offering with the Addition of Preformulation and Formulation Capability
Abzena has augmented existing discovery to GMP drug substance and Antibody Drug Conjugates (ADC) manufacturing and associated analytical services with numerous investments in preformulation and formulation capabilities to enable de-risking of CTA/IND candidates.
Abzena Announces 20m$ Investment into Expansion of Integrated Biotherapeutics Offering (Biologics Drug Substance and ADC) and Makes Key Executive Appointment
Significant increase in capacity to 2000 L scale in new GMP facility, addition of extra cell line development capacity and extra chemistry laboratory space. Appointment of Richard Milbank as Chief Financial Officer
Ken Cunningham, Chairman of Abzena Limited, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO) following completion of the Acquisition by Welsh, Carson, Anderson & Stowe (WCAS)
Dr. Goldman will focus his efforts on the growth of Abzena as the leading provider of outsourced and integrated services in the biologics early development space by establishing new partnerships with clients, building internal manufacturing capacity and pursuing strategic acquisitions.
Abzena Announces a Research and Licence Agreement with Tmunity Therapeutics, a T Cell Engineering Company
Abzena, plc has signed an antibody humanisation agreement with Tmunity Therapeutics
Abzena plc has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US).
This agreement allows a seamless transition of current projects, together with the capabilities, resources and expertise from the TDL to Abzena.
Abzena provides an update on its UK and U.S. facilities.